|
Valoración DCF de Jazz Pharmaceuticals plc (JAZZ) |
Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
Predeterminadas Para Un Uso Rápido Y Eficiente
Compatible con MAC / PC, completamente desbloqueado
No Se Necesita Experiencia; Fáciles De Seguir
Jazz Pharmaceuticals plc (JAZZ) Bundle
¡Obtenga información sobre su análisis de valoración de Jazz Pharmaceuticals PLC (Jazz) con nuestra calculadora DCF de última generación! Esta plantilla de Excel viene precargada de datos reales (jazz), lo que le permite ajustar preventos y supuestos para determinar con precisión el valor intrínseco de Jazz Pharmaceuticals PLC.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,363.6 | 3,094.2 | 3,659.4 | 3,834.2 | 4,069.0 | 4,680.1 | 5,383.0 | 6,191.5 | 7,121.5 | 8,191.1 |
| Revenue Growth, % | 0 | 30.91 | 18.26 | 4.78 | 6.12 | 15.02 | 15.02 | 15.02 | 15.02 | 15.02 |
| EBITDA | 649.7 | 718.4 | 553.8 | 1,226.1 | 1,368.5 | 1,230.4 | 1,415.2 | 1,627.7 | 1,872.2 | 2,153.4 |
| EBITDA, % | 27.49 | 23.22 | 15.13 | 31.98 | 33.63 | 26.29 | 26.29 | 26.29 | 26.29 | 26.29 |
| Depreciation | 278.3 | 552.5 | 629.5 | 638.7 | 660.1 | 746.1 | 858.2 | 987.0 | 1,135.3 | 1,305.8 |
| Depreciation, % | 11.77 | 17.86 | 17.2 | 16.66 | 16.22 | 15.94 | 15.94 | 15.94 | 15.94 | 15.94 |
| EBIT | 371.4 | 165.9 | -75.7 | 587.4 | 708.4 | 484.3 | 557.0 | 640.7 | 736.9 | 847.6 |
| EBIT, % | 15.71 | 5.36 | -2.07 | 15.32 | 17.41 | 10.35 | 10.35 | 10.35 | 10.35 | 10.35 |
| Total Cash | 2,132.8 | 591.4 | 881.5 | 1,626.3 | 2,992.9 | 2,334.5 | 2,685.1 | 3,088.4 | 3,552.3 | 4,085.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 396.5 | 563.4 | 651.5 | 705.8 | 716.8 | 831.3 | 956.1 | 1,099.7 | 1,264.9 | 1,454.9 |
| Account Receivables, % | 16.78 | 18.21 | 17.8 | 18.41 | 17.62 | 17.76 | 17.76 | 17.76 | 17.76 | 17.76 |
| Inventories | 95.4 | 1,072.7 | 714.1 | 597.0 | 480.4 | 801.2 | 921.5 | 1,059.9 | 1,219.1 | 1,402.3 |
| Inventories, % | 4.04 | 34.67 | 19.51 | 15.57 | 11.81 | 17.12 | 17.12 | 17.12 | 17.12 | 17.12 |
| Accounts Payable | 26.9 | 100.3 | 90.8 | 102.8 | 77.9 | 107.2 | 123.3 | 141.8 | 163.2 | 187.7 |
| Accounts Payable, % | 1.14 | 3.24 | 2.48 | 2.68 | 1.91 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 |
| Capital Expenditure | -379.3 | -45.5 | -498.2 | -24.0 | -48.1 | -308.3 | -354.6 | -407.9 | -469.1 | -539.6 |
| Capital Expenditure, % | -16.05 | -1.47 | -13.61 | -0.62495 | -1.18 | -6.59 | -6.59 | -6.59 | -6.59 | -6.59 |
| Tax Rate, % | -19.09 | -19.09 | -19.09 | -19.09 | -19.09 | -19.09 | -19.09 | -19.09 | -19.09 | -19.09 |
| EBITAT | 325.7 | 483.7 | -44.3 | 826.2 | 843.7 | 432.2 | 497.1 | 571.8 | 657.7 | 756.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -240.3 | -80.2 | 348.0 | 1,515.6 | 1,536.4 | 464.1 | 771.6 | 887.5 | 1,020.7 | 1,174.1 |
| WACC, % | 4.5 | 4.72 | 3.99 | 4.72 | 4.72 | 4.53 | 4.53 | 4.53 | 4.53 | 4.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 3,722.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 1,198 | |||||||||
| Terminal Value | 47,306 | |||||||||
| Present Terminal Value | 37,904 | |||||||||
| Enterprise Value | 41,627 | |||||||||
| Net Debt | 3,749 | |||||||||
| Equity Value | 37,877 | |||||||||
| Diluted Shares Outstanding, MM | 66 | |||||||||
| Equity Value Per Share | 573.84 |
What You Will Receive
- Flexible Forecast Inputs: Adjust key assumptions (growth %, margins, WACC) effortlessly to explore various scenarios.
- Comprehensive Data: Jazz Pharmaceuticals' financial information pre-loaded to facilitate your analysis.
- Instant DCF Outputs: The template automatically computes Net Present Value (NPV) and intrinsic value for you.
- Tailored and Professional: A sleek Excel model designed to meet your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life JAZZ Financials: Pre-filled historical and projected data for Jazz Pharmaceuticals plc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Jazz’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Jazz’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download and open the Excel file containing Jazz Pharmaceuticals plc’s (JAZZ) financial data.
- 2. Modify Assumptions: Adjust key parameters such as growth projections, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to understand different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation insights to enhance your decision-making process.
Why Choose This Calculator?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Comprehensive Data: Jazz Pharmaceuticals' historical and projected financials are preloaded for precision.
- Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Clear Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance leads you through the calculation process.
Who Should Use Jazz Pharmaceuticals plc (JAZZ)?
- Investors: Make informed decisions with a comprehensive analysis of Jazz Pharmaceuticals' market performance.
- Pharmaceutical Analysts: Streamline your research with detailed insights into product pipelines and financials.
- Consultants: Easily tailor presentations or reports focused on Jazz Pharmaceuticals for your clients.
- Healthcare Enthusiasts: Enhance your knowledge of the pharmaceutical industry by exploring real-world case studies of Jazz Pharmaceuticals.
- Educators and Students: Utilize it as a valuable resource in pharmaceutical and finance courses.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Jazz Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Jazz Pharmaceuticals.
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.